EC approves Vertex’s Orkambi for cystic fibrosis in children
2023-07-05
上市批准细胞疗法临床研究
Preview
来源: Pharmaceutical Technology
Approximately 300 paediatric CF patients with two copies of the F508del mutation are eligible to receive Vertex’s Orkambi. Credit: Vertex Pharmaceuticals.
The European Commission (EC) has approved extending the label for Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) to treat cystic fibrosis (CF) in children aged between one and two years.
This oral treatment is indicated for paediatric patients with a cystic fibrosis transmembrane conductance regulator (CFTR) gene possessing two copies of the F508del mutation.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Teicoplanin in Cystic Fibrosis GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ensifentrine in Cystic Fibrosis GlobalData
View allCompanies IntelligenceVertex Pharmaceuticals IncVertex CorpLonza AGView all
Approximately 300 such patients are now eligible for the first time to receive a drug that can treat the underlying cause of the disease.
It is currently approved for use in the UK, US, Canada and Australia for treating CF patients aged one year or above.
Orkambi combines lumacaftor and ivacaftor, and aids in hydrating and eliminating mucus from the airways.
Vertex Pharmaceuticals CEO, global medicines development and medical affairs executive vice-president Carmen Bozic stated: “This approval will offer some of the youngest children with cystic fibrosis the chance of improved outcomes, by treating their disease at a young age.
“With this important milestone, we move ever closer to our goal of providing medicines that treat the underlying cause of CF to all people living with the disease.”
In June 2023, the company signed a strategic collaboration with Lonza to set up a facility at Portsmouth, New Hampshire, US, to produce Vertex’s cell therapies for type 1 diabetes.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。